Key facts: Evonik rejects BASF bid; shares fall 23%; restructuring
Evonik rejected BASF's €24-per-share cash offer, valued at €11.2 billion, citing weak industrial rationale. Evonik shares fell 23% to €16.75. The company plans restructuring, including divestments and job cuts. Political resistance and RAG Foundation's 43% stake may further complicate the deal.
How this was made

The 30-second read
Why it matters
The failed bid eliminates a possible takeover premium, leading to a sharp sell‑off in EVK and heightened scrutiny of BASF's M&A strategy.
Market read
The news drives immediate downside risk for EVK and may affect peer valuations in the European chemicals sector.
What to watch
Potential regulatory hurdles and political resistance in North Rhine‑Westphalia may have made the bid unattractive regardless of price.
Background
Evonik Industries AG (EVK) is a leading German specialty chemicals group. BASF, a rival chemicals giant, attempted a €11.2 bn cash takeover that was turned down.
Market effects
European chemicals sector may see broader sell‑off as takeover speculation fades.
German market likely to dip on the news, especially peers like BASF.
Limited to chemicals and M&A sentiment; no immediate global macro effect.
Counterpoint
The rejection could signal confidence in Evonik's standalone strategy, presenting a buying opportunity at a discounted price.
Key entities
- CompanyEvonik Industries AG
German specialty chemicals producer, ticker EVK.
- CompanyBASF SE
German chemicals conglomerate that made the rejected cash offer.

